172 related articles for article (PubMed ID: 35574429)
1. Cost-effectiveness analysis of ferric carboxymaltose
Argüelles-Arias F; Bermejo F; Borrás-Blasco J; Domènech E; Sicilia B; Huguet JM; de Arellano AR; Valentine WJ; Hunt B
Therap Adv Gastroenterol; 2022; 15():17562848221086131. PubMed ID: 35574429
[TBL] [Abstract][Full Text] [Related]
2. Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.
Aksan A; Schoepfer A; Juillerat P; Vavricka S; Bettencourt M; Ramirez de Arellano A; Gavata S; Morin N; Valentine WJ; Hunt B
Adv Ther; 2021 Jan; 38(1):660-677. PubMed ID: 33216324
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Cost-Effectiveness of Iron Formulations for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease in the UK.
Aksan A; Beales ILP; Baxter G; de Arellano AR; Gavata S; Valentine WJ; Hunt B
Clinicoecon Outcomes Res; 2021; 13():541-552. PubMed ID: 34168471
[TBL] [Abstract][Full Text] [Related]
5. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
6. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
[TBL] [Abstract][Full Text] [Related]
7. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
8. Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis.
Kwong WJ; Wang K; Wang P; Boccia R
Drugs Real World Outcomes; 2024 Jun; 11(2):251-261. PubMed ID: 38502304
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
10. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
[TBL] [Abstract][Full Text] [Related]
13. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease.
Carman N; Muir R; Lewindon P
Transl Pediatr; 2019 Jan; 8(1):28-34. PubMed ID: 30881896
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study.
Rosati A; Conti P; Berto P; Molinaro S; Baldini F; Egan CG; Panichi V;
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142929
[TBL] [Abstract][Full Text] [Related]
15. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Lichtenstein GR; Onken JE
Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
[TBL] [Abstract][Full Text] [Related]
16. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
Calvet X; Ruíz MÀ; Dosal A; Moreno L; López M; Figuerola A; Suarez D; Miquel M; Villoria A; Gené E
PLoS One; 2012; 7(9):e45604. PubMed ID: 23029129
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
[TBL] [Abstract][Full Text] [Related]
20. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2017; 9():475-483. PubMed ID: 28848355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]